Although SB 290157 is an effective and selective C3aR antagonist in some experimental animal models, the preclinical and clinical evidence of SB 290157 needs to be explored to prevent dietary obesity, metabolic dysfunction and NAFLD in the coming future. This evidence concerns the gene C3AR1 and obesity due to melanocortin 4 receptor deficiency.